Fluorodeoxyglucose F18, (2-deoxy-2[18F]fluoro-D-glucose), Injection is an intravenous, diagnostic radiopharmaceutical for Positron Emission Tomography (PET).
FDG is absorbed in tissues in a manner similar to glucose, to assist in the evaluation of malignancy in patients with known or suspected abnormalities .
As it is absorbed, the hypermetabolic process is “marked” by the isotope included in the compound. FDG is currently the strongest practical work tool in the PET sector.
Sodium Fluoride F-18 [F-18 NaF] Well known PET agents in imaging of skeletal system. Its usage in clinical practice including primary and secondary bone tumors and other skeletal disorders such as arthritis, osteomyelitis, and fracture has many advantages to conventional bone scintigraphy and other imaging modalities.
Gallium-68 DOTA-1-Nal3-octreotide PET imaging with gallium-68 has major bearings in current and future clinical practice. Its has cleared the way for somatostatin receptor imaging with a viable PET agent, in a variety of tumours, particularly diagnosis of neuroendocrine tumors.
